Blood · 2000 · 285 citations · 32 references
MedicineCancer BiologyMolecular BiologyCancer GeneticsMolecular OncologyOncogenesLymphoid NeoplasmsLymphoid TumorsMyc Family OncogenesOncogenic Signaling PathwaysC-myc RegulationMyc In LymphomaMyc Post-translational ModificationsMyc Proteasomal DegradationMyc UbiquitinationOncogenic Myc SignalingProteasomal TurnoverProteasome-mediated Degradation
The c-myc proto-oncogene encodes a short-lived transcription factor that plays an important role in cell cycle regulation, differentiation and apoptosis. c-myc is often rearranged in tumors resulting in deregulated expression. In addition, mutations in the coding region of c-myc are frequently found in human lymphomas, a hot spot being the Thr58 phosphorylation site, a mutation shown to enhance the transforming capacity of c-Myc. It is, however, still unclear in what way this mutation affects c-Myc activity. Our results show that proteasome-mediated turnover of c-Myc is substantially impaired in Burkitt's lymphoma cells with mutated Thr58 or other mutations that abolish Thr58 phosphorylation, whereas endogenous or ectopically expressed wild type c-Myc proteins turn over at normal rates in these cells. Myc Thr58 mutants expressed ectopically in other cell types also exhibit reduced proteasome-mediated degradation, which correlates with a substantial decrease in their ubiquitination. These results suggest that ubiquitin/proteasome-mediated degradation of c-Myc is triggered by Thr58 phosphorylation revealing a new important level of control of c-Myc activity. Mutation of Thr58 in lymphoma thus escapes this regulation resulting in accumulation of c-Myc protein, likely as part of the tumor progression. (Blood. 2000;95:2104-2110)
32
β‐catenin is a target for the ubiquitin–proteasome pathway
Hermann Aberle, Andreas Bauer, Jörg Stappert et al. · The EMBO Journal · 1997 · 2.5K citations